MK-0159 is an orally active, potent and selective CD38 inhibitor (h/m/r CD38 IC50 = 22/3/70 nM) that increases extra- and intracellular NAD+ levels in high CD38-expressing human epithelial A549 cultures, as well as intracellular NAD+/NADP+ in HMVECs (0.3-50 µM). MK-0159 (3-30 mg/kg p.o.) increases systemic NAD+ and decreases ADPR levels in mice, providing protection from myocardial damage upon cardiac I/R injury in vivo (30 mg/kg p.o.).
Potent and selective CD38 inhibitor that protects mice from myocardial damage upon cardiac I/R injury in vivo.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD+, is up-regulated in CD8+ T cells of SLE patients and correlates
Journal of medicinal chemistry, 65(13), 9418-9446 (2022-06-29)
CD38 is one of the major nicotinamide adenine dinucleotide (NAD+)- and nicotinamide adenine dinucleotide phosphate (NADP+)-consuming enzymes in mammals. NAD+, NADP+, and their reduced counterparts are essential coenzymes for numerous enzymatic reactions, including the maintenance of cellular and mitochondrial redox
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
